Drug Trial Radar · NCT06905210
Study of New Antiandrogenic Progestogen + Low-dose Estrogen for Moderate Acne Vulgaris
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
531
Planned (sponsor's estimate)
Start
Aug 24, 2026
Primary completion
Feb 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- Eurofarma Laboratorios S.A.Industry
- Sponsor type
- Industry
- First posted
- Apr 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 14 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase III randomized, double-blind, placebo-controlled, adaptive, multicenter study evaluates the efficacy and safety of a new concentration of the fixed-dose combination EF190 in women with moderate acne vulgaris over six 28-day treatment cycles. Eligible participants will be randomized (2:1) to receive either the experimental drug or placebo alongside standard skincare. The study includes five in-person visits (screening, randomization, and three follow-ups) and three phone contacts (cycles 2, 4, and 5) to monitor adherence, adverse events, and contraceptive use. A subgroup will undergo additional exploratory assessments, including acne questionnaires, ovarian activity tests, photographic documentation, and specialized lab/ultrasound exams.
Conditions
- Acne Vulgaris
- Acne Vulgaris on the Face
Interventions
Experimental drug (Cyproterone Acetate 2 mg and Ethinyl Estradiol 0.02 mg)Drug
Cyproterone acetate 2 mg and ethinyl estradiol 0.02 mg film-coated tablets administered in a 24+4 regimen. Each treatment pack contains one 28-tablet calendar blister composed of 24 active tablets and 4 inactive tablets. Participants will receive treatment for 6 consecutive 28-day cycles during the double-blind treatment period.
PlaceboDrug
Placebo film-coated tablets administered in a 24+4 regimen. Each treatment pack contains one 28-tablet calendar blister composed of 24 placebo tablets and 4 inactive placebo tablets. Participants will receive treatment for 6 consecutive 28-day cycles during the double-blind treatment period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absolute reduction from baseline in the number of inflammatory acne lesions assessed at Cycle 6.Time frame: 24 weeks
- Absolute reduction from baseline in the total number of acne lesions assessed at Cycle 6.Time frame: 24 weeks
- Change from Baseline of participants with scores 0 or 1 in the Static Investigator Global Assessment (ISGA) at cycle 6.Time frame: 24 weeks
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Clinica Ibis Salvador
Salvador, Estado de Bahia, Brazil · Recruiting
Instituto de Gestão Estratégica de Saúde do Distrito Federal-IGESDF
Brasília, Federal District, Brazil · Recruiting
ICF Ciências Farmacêutica - Unidade Clínica
Goiânia, Goiás, Brazil · Recruiting
Centro de Pesquisa Clínica - Hospital Ruy Azeredo
Goiânia, Goiás, Brazil · Recruiting
Norte Pesquisa Clínica
Belém, Pará, Brazil · Recruiting
Genthe Pesquisa Clínica
Rio de Janeiro, Rio de Janeiro, Brazil · Recruiting
Artha Pesquisas Clínicas
Rio de Janeiro, Rio de Janeiro, Brazil · Recruiting
Liga Norte Riograndense Contra o Câncer
Natal, Rio Grande do Norte, Brazil · Recruiting
Hospital de Clínicas de Passo Fundo
Passo Fundo, Rio Grande do Sul, Brazil · Recruiting
Centro de Pesquisa Clínica Mãe de Deus/AESC
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Hospital Universitário São Francisco na Providência de Deus - HUSF
Bragança Paulista, São Paulo, Brazil · Recruiting
CLINICA GERAL INVESTIGA LTDA (Allergisa)
Campinas, São Paulo, Brazil · Recruiting
Synvia
Campinas, São Paulo, Brazil · Recruiting
Eurofarma Laboratórios S.A
Itapevi, São Paulo, Brazil · Recruiting
CIPES
São José dos Campos, São Paulo, Brazil · Recruiting
Synvia
São Paulo, São Paulo, Brazil · Recruiting
Kosmoscience
Valinhos, São Paulo, Brazil · Recruiting
Azidus
Valinhos, São Paulo, Brazil · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.